SLC6A16 Antibody

What is SLC6A16 and why is it studied?

SLC6A16 (also known as NTT5) is a member of the solute carrier family 6 (SLC6) of transporters, which are integral membrane proteins characterized by Na⁺-dependent translocation of small amino acid or amino acid-like substrates . The SLC6 family includes transporters for neurotransmitters such as serotonin, dopamine, norepinephrine, and GABA, as well as other substrates like taurine, creatine, and various amino acids . These transporters are associated with numerous human diseases and disorders, including attention deficit hyperactivity disorder (ADHD), addiction, X-linked mental retardation, Hartnup disorder, hyperekplexia, Tourette syndrome, schizophrenia, Parkinson's disease, autism, and various mood disorders . This extensive disease association makes SLC6A16 and related transporters critical targets for research and therapeutic development.

What applications are SLC6A16 antibodies validated for?

Based on available research and commercial resources, SLC6A16 antibodies have been validated for several applications:

• Western Blot (WB): Used to detect SLC6A16 protein in cell lysates such as HEK293T and H9C2 cells, with an expected molecular weight of approximately 82 kDa .

• Immunohistochemistry (IHC): Applied to detect SLC6A16 in paraffin-embedded human tissue samples, particularly brain tissue .

• Immunocytochemistry/Immunofluorescence (ICC/IF): Validated for detection of SLC6A16 in human samples with recommended dilutions of 1-4 μg/mL .

• ELISA: Some antibodies are validated for ELISA application with recommended dilutions of approximately 1:40000 .

What species reactivity can be expected from commonly available SLC6A16 antibodies?

Most commercially available SLC6A16 antibodies demonstrate reactivity with human samples . Some antibodies show cross-reactivity with rat samples as well . When selecting an antibody for your research, it's important to check the specific reactivity profile, as not all antibodies will work across different species due to sequence variations in the immunogenic regions. Some vendors provide information about homology-based prediction for untested species, but it's recommended to validate antibody performance in your specific experimental system .

What is the recommended storage protocol for SLC6A16 antibodies?

For short-term storage, SLC6A16 antibodies should be stored at 4°C . For long-term storage, it is recommended to aliquot the antibody and store at -20°C . Repeated freeze/thaw cycles should be avoided to maintain antibody integrity and performance . Most commercial SLC6A16 antibodies are supplied in buffer systems containing preservatives (such as sodium azide) and stabilizers (such as glycerol), which help maintain antibody function during storage .

How should I optimize Western blot protocols for detecting SLC6A16?

Optimizing Western blot protocols for SLC6A16 detection requires attention to several key factors:

• Sample preparation: Since SLC6A16 is a membrane protein (82 kDa), use extraction buffers containing appropriate detergents to solubilize membrane proteins effectively. Complete cell lysis of HEK293T or H9C2 cells has been successfully used in previous studies .

• Protein denaturation: Heat samples at 95°C for 5 minutes in Laemmli buffer containing SDS and a reducing agent. Avoid prolonged heating which may cause aggregation of membrane proteins.

• Gel percentage: Use 8-10% polyacrylamide gels for optimal resolution of the 82 kDa SLC6A16 protein .

• Transfer conditions: For large membrane proteins like SLC6A16, use lower voltage transfer for longer duration or semi-dry transfer systems with specialized buffers for high molecular weight proteins.

• Blocking conditions: 5% non-fat dry milk or BSA in TBST is typically effective, but optimization may be required.

• Antibody dilution: Start with the manufacturer's recommended dilution (varies by antibody) and optimize as needed. For some commercial antibodies, dilutions for WB applications have been established .

• Detection method: Use HRP-conjugated secondary antibodies with enhanced chemiluminescence for sensitive detection. Longer exposure times may be necessary.

If non-specific bands appear, consider additional washing steps or adjusting antibody concentration. Validation with positive control lysates (such as HEK293T cells) is recommended .

What are the critical considerations for immunohistochemical detection of SLC6A16 in tissue sections?

When performing immunohistochemistry to detect SLC6A16 in tissue sections, researchers should consider:

Human brain tissue sections have been successfully used to detect SLC6A16 expression patterns using immunohistochemistry .

How can I validate the specificity of an SLC6A16 antibody for my research?

Validating antibody specificity is crucial for obtaining reliable results. For SLC6A16 antibodies, consider the following validation approaches:

• Positive and negative control samples: Use cell lines or tissues known to express or lack SLC6A16. HEK293T and H9C2 cell lines have been used as positive controls in Western blot applications .

• Knockdown/knockout verification: If possible, use siRNA knockdown or CRISPR/Cas9 knockout models to demonstrate reduction or elimination of the detected signal.

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide before application to demonstrate that binding can be specifically blocked. For SLC6A16 antibodies developed against synthetic peptides, this information is often available from manufacturers .

• Multiple antibody verification: Use multiple antibodies targeting different epitopes of SLC6A16 to confirm consistent detection patterns.

• Cross-reactivity assessment: If working with non-human samples, verify species cross-reactivity through sequence homology analysis and experimental validation.

• Recombinant protein controls: Use purified recombinant SLC6A16 protein as a positive control to confirm antibody specificity and sensitivity.

• Mass spectrometry validation: For definitive verification, consider immunoprecipitation followed by mass spectrometry to confirm the identity of the detected protein.

Some commercial SLC6A16 antibodies have undergone specificity validation through protein array testing against the target protein plus 383 other non-specific proteins , providing additional confidence in antibody performance.

What are the challenges in detecting membrane proteins like SLC6A16 and how can they be overcome?

Detecting membrane proteins like SLC6A16 presents several challenges:

• Protein solubilization: SLC6A16, as a membrane protein with 12 transmembrane domains , requires effective solubilization. Use detergents such as SDS, Triton X-100, or CHAPS at optimized concentrations. For Western blotting, avoid excessive heating which may cause aggregation.

• Epitope accessibility: The complex folding and membrane embedding of SLC6A16 can mask epitopes. For fixed tissues or cells, optimize antigen retrieval methods. For some applications, non-denaturing conditions may better preserve conformational epitopes.

• Protein abundance: SLC6A16 may be expressed at relatively low levels in some tissues. Consider signal amplification methods such as tyramide signal amplification (TSA) for IHC/IF or more sensitive detection reagents for Western blotting.

• Post-translational modifications: SLC6A16, like other SLC6 family members, undergoes glycosylation and other modifications that can affect antibody recognition. Treatment with glycosidases may be necessary to obtain consistent results.

• Subcellular localization: For accurate detection of membrane-localized SLC6A16, subcellular fractionation protocols may be required to enrich membrane proteins before Western blotting.

• Cross-reactivity with similar transporters: The SLC6 family contains multiple members with structural similarities . Carefully select antibodies that target unique regions of SLC6A16 to avoid cross-reactivity.

• Fixation artifacts: For microscopy applications, evaluate different fixation protocols (e.g., PFA vs. methanol) to determine which best preserves SLC6A16 epitopes while maintaining cellular structure.

How does SLC6A16 structure relate to function, and how can antibodies help elucidate this relationship?

SLC6A16 belongs to the SLC6 family of transporters, which generally have 12 membrane spanning domains (TM) with intracellular N and C termini . The structure-function relationship of these transporters has been significantly informed by the high-resolution structure of the bacterial leucine transporter LeuT, a bacterial homolog of SLC6 transporters .

Key structural features that antibodies can help investigate include:

• Transmembrane domains: Antibodies targeting specific transmembrane regions can help determine which domains are critical for substrate binding and translocation.

• Extracellular and intracellular loops: These regions are often more accessible to antibodies and can provide insights into regulatory mechanisms. In particular, the extended extracellular loop 2 domain (EL2) between TMs 3 and 4, which contains a critical disulfide bond, is an important structural feature in eukaryotic SLC6 transporters .

• N and C termini: Eukaryotic SLC6 transporters, including SLC6A16, have significantly longer N and C termini compared to prokaryotic members. These regions mediate complex regulatory processes such as protein trafficking, ion stoichiometry, and function . Antibodies targeting these regions can help elucidate these regulatory mechanisms.

• Post-translational modifications: Antibodies can be used to detect modifications such as glycosylation and palmitoylation, which are present in eukaryotic SLC6 transporters but absent in prokaryotic members .

• Oligomerization states: There is increasing evidence that the oligomeric state of SLC6 transporters can impact proper trafficking to the plasma membrane and may modulate function and regulation . Antibodies can be used in combination with techniques like FRET or proximity ligation assays to investigate oligomerization.

For research focusing on structure-function relationships, epitope-specific antibodies can be particularly valuable, as they can target different domains of the protein to elucidate their roles in transport function.

What experimental approaches can be used to study SLC6A16 expression and localization in different cell types?

Several experimental approaches using antibodies can be employed to study SLC6A16 expression and localization:

• Immunohistochemistry/Immunofluorescence:

  • Paraffin-embedded or frozen tissue sections can be used to determine tissue-specific expression patterns .

  • Double immunofluorescence with cell type-specific markers can identify which cell populations express SLC6A16.

  • Confocal microscopy can provide detailed subcellular localization information.

• Flow cytometry:

  • For permeabilized cells, intracellular staining with SLC6A16 antibodies can quantify expression levels across cell populations.

  • Multiparameter analysis can correlate SLC6A16 expression with cell type markers or activation states.

• Western blotting:

  • Comparison of SLC6A16 protein levels across different cell types or tissues .

  • Subcellular fractionation followed by Western blotting can determine protein distribution between membrane and cytosolic compartments.

• Immunoprecipitation:

  • Can be used to isolate SLC6A16 and identify interacting proteins that may regulate its localization or function.

• Live cell imaging:

  • Using fluorescently tagged anti-SLC6A16 antibody fragments to track protein dynamics in live cells.

• Electron microscopy:

  • Immunogold labeling with SLC6A16 antibodies for ultrastructural localization at the subcellular level.

• In situ hybridization combined with immunohistochemistry:

  • To correlate mRNA expression with protein localization and potentially identify post-transcriptional regulation mechanisms.

These approaches can be particularly valuable for understanding how SLC6A16 expression and localization may be altered in disease states or in response to pharmacological interventions.

How can SLC6A16 antibodies be used to investigate potential roles in disease processes?

SLC6A16 antibodies can be instrumental in investigating disease associations through several research approaches:

• Differential expression analysis:

  • Compare SLC6A16 protein levels in normal versus diseased tissues using Western blotting or IHC.

  • Quantitative image analysis of immunohistochemistry can provide spatial information about altered expression patterns.

• Biomarker development:

  • Assess whether SLC6A16 protein levels correlate with disease progression or treatment response.

  • The SLC6 family has links to various neurological and psychiatric disorders, including ADHD, X-linked mental retardation, addiction, Tourette syndrome, schizophrenia, Parkinson's disease, and autism .

• Functional studies:

  • Use antibodies to block SLC6A16 function in cellular models to assess physiological consequences.

  • Combine with transport assays to determine how disease-associated mutations affect transport activity.

• Protein-protein interactions:

  • Immunoprecipitation with SLC6A16 antibodies followed by mass spectrometry to identify disease-relevant interaction partners.

  • Co-immunoprecipitation to validate specific interactions and how they may be altered in disease states.

• Post-translational modifications:

  • Investigate disease-associated changes in glycosylation, phosphorylation, or other modifications of SLC6A16 using modification-specific antibodies.

• Genetic correlation studies:

  • Correlate SLC6A16 protein levels with genetic variants identified in genome-wide association studies (GWAS).

• Drug development applications:

  • Use antibodies to screen for compounds that modulate SLC6A16 expression or localization.

  • Evaluate the effects of potential therapeutic compounds on SLC6A16 in relevant disease models.

Given the association of SLC6 transporters with various human diseases and disorders , SLC6A16 antibodies provide valuable tools for investigating potential pathological mechanisms and identifying new therapeutic targets.

What considerations are important when analyzing SLC6A16 in transport studies?

When using antibodies to complement transport studies of SLC6A16, consider the following:

• Expression verification:

  • Confirm SLC6A16 expression in your experimental system using Western blotting or immunofluorescence before conducting transport assays.

  • Quantify relative expression levels across different experimental conditions to normalize transport data.

• Subcellular localization:

  • Use immunofluorescence to verify proper plasma membrane localization, as transport function requires correct membrane insertion.

  • Determine whether experimental manipulations alter SLC6A16 subcellular distribution, which could indirectly affect transport activity.

• Structural integrity:

  • SLC6A16, like other SLC6 transporters, has a structure characterized by 12 transmembrane domains . Ensure that any epitope tags or modifications for transport studies don't disrupt critical structural elements.

• Antibody interference:

  • Be aware that antibody binding may directly affect transport function if using antibodies in live-cell transport assays.

  • Consider using Fab fragments instead of whole IgG molecules to minimize potential steric hindrance.

• Oligomerization assessment:

  • Evidence suggests that oligomerization can impact SLC6 transporter trafficking and function . Use antibodies in approaches like FRET or crosslinking studies to assess oligomeric state and its impact on transport.

• Integration with biophysical methods:

  • Correlate antibody-based protein detection with electrophysiological methods or fluorescent substrate tracking to build comprehensive transport models.

• Comparative analysis with other SLC6 family members:

  • Use specific antibodies to different SLC6 transporters to determine relative contributions to observed transport phenotypes.

Understanding the structure-function relationship of SLC6A16, particularly its 12 transmembrane domain organization and the role of intracellular N and C termini in regulation , is essential for interpreting transport data accurately.

What are common challenges when using SLC6A16 antibodies and how can they be addressed?

Researchers often encounter several challenges when using SLC6A16 antibodies:

• High background in immunostaining:

  • Optimize blocking conditions (try different blocking agents like BSA, normal serum, or commercial blockers).

  • Increase washing duration and frequency.

  • Dilute primary antibody further or reduce incubation time.

  • For tissues with high endogenous biotin, use avidin/biotin blocking kits if using biotin-based detection systems.

• Weak or absent signal in Western blots:

  • Ensure adequate protein loading (SLC6A16 may be expressed at low levels).

  • Optimize transfer conditions for the 82 kDa protein .

  • Increase antibody concentration or incubation time.

  • Use more sensitive detection systems (enhanced chemiluminescence or fluorescent secondaries).

  • Consider alternative extraction methods to improve membrane protein solubilization.

• Multiple bands or unexpected molecular weight:

  • Verify if bands represent differentially glycosylated forms of SLC6A16.

  • Test sample treatment with deglycosylation enzymes to confirm glycosylation status.

  • Compare results with positive control samples like HEK293T cell lysates .

  • Consider the possibility of protein degradation and add protease inhibitors during sample preparation.

• Inconsistent immunostaining patterns:

  • Standardize fixation protocols and times.

  • Optimize antigen retrieval conditions.

  • Ensure consistent antibody dilutions and incubation times.

  • Use automated staining platforms for better reproducibility if available.

• Poor antibody specificity:

  • Validate with peptide competition assays using the immunizing peptide.

  • Compare results with alternative SLC6A16 antibodies targeting different epitopes.

  • Verify results in positive and negative control samples.

• Cross-reactivity with other SLC6 family members:

  • Choose antibodies raised against unique regions of SLC6A16 rather than conserved domains.

  • Validate specificity through knockout/knockdown approaches when possible.

How can I optimize double immunofluorescence protocols involving SLC6A16 antibodies?

Optimization of double immunofluorescence protocols with SLC6A16 antibodies requires attention to several factors:

• Antibody compatibility:

  • Ensure primary antibodies are raised in different host species to avoid cross-reactivity of secondary antibodies.

  • If both primaries are from the same species, consider direct conjugation of one antibody or sequential staining protocols.

• Signal balancing:

  • Adjust antibody dilutions to achieve comparable signal intensities (SLC6A16 antibodies are typically used at 1-4 μg/mL for immunofluorescence ).

  • Select fluorophores with distinct emission spectra and minimal bleed-through.

  • Consider signal amplification for the weaker antigen (e.g., tyramide signal amplification).

• Protocol sequence optimization:

  • Test simultaneous versus sequential primary antibody incubations.

  • For sequential protocols, apply the antibody detecting the lower abundance protein first.

  • Include stringent washing steps between antibody applications.

• Fixation and permeabilization:

  • Different antigens may require different fixation methods; optimize to preserve both epitopes.

  • Test various permeabilization agents (Triton X-100, saponin, methanol) to find optimal conditions for both antigens.

• Antigen retrieval compatibility:

  • If heat-induced epitope retrieval is needed, ensure conditions are compatible with both antigens.

  • Consider dual retrieval protocols if antigens have different requirements.

• Controls for co-localization studies:

  • Include single-stained controls to assess bleed-through.

  • Use positive controls where co-localization status is known.

  • Apply appropriate quantitative co-localization analysis methods.

• Imaging considerations:

  • Use sequential scanning on confocal microscopes to minimize cross-talk.

  • Apply consistent acquisition settings across experimental conditions.

  • Consider super-resolution microscopy for detailed co-localization studies of membrane proteins.

What quality control metrics should be applied when validating a new lot of SLC6A16 antibody?

When validating a new lot of SLC6A16 antibody, implement the following quality control measures:

• Side-by-side comparison with previous lot:

  • Perform Western blot analysis using the same samples and protocol.

  • Compare immunostaining patterns in positive control tissues or cells.

  • Quantify signal-to-noise ratios to detect sensitivity differences.

• Reproducibility assessment:

  • Test technical replicates to evaluate consistency.

  • Have multiple researchers perform the same protocol to assess operator-independent performance.

• Specificity verification:

  • Confirm expected molecular weight (82 kDa) in Western blot .

  • Verify tissue or cellular localization patterns match known distribution.

  • Perform peptide competition assay if the immunizing peptide sequence is available.

• Sensitivity testing:

  • Prepare a dilution series of positive control lysates to determine detection limits.

  • Compare minimal detectable concentration with previous lot specifications.

• Cross-reactivity evaluation:

  • Test antibody on samples from multiple species if cross-reactivity is claimed.

  • Verify absence of signal in negative control samples.

• Application-specific validation:

  • For Western blotting: Check for clean bands at expected molecular weight using HEK293T or H9C2 cell lysates .

  • For IHC/ICC: Verify cellular localization patterns in human brain tissue or other relevant samples .

  • For ELISA: Generate standard curves and compare detection ranges with previous lot data.

• Stability assessment:

  • Test antibody performance after multiple freeze-thaw cycles to ensure robustness.

  • Evaluate performance after storage at recommended conditions (4°C short-term or -20°C long-term) .

• Documentation:

  • Record lot-specific optimal working dilutions for each application.

  • Document any observed differences from previous lots in a laboratory notebook.

Companies often provide lot-specific validation data , which should be reviewed carefully and compared with in-house validation results.

How can SLC6A16 antibodies be leveraged in drug development and therapeutic research?

SLC6A16 antibodies can serve multiple functions in drug development and therapeutic research:

• Target validation:

  • Confirm SLC6A16 expression in disease-relevant tissues using immunohistochemistry.

  • Quantify expression changes in disease models using Western blotting to validate therapeutic relevance.

• High-throughput screening support:

  • Develop ELISA or other antibody-based assays to screen compounds that modulate SLC6A16 expression or localization.

  • Use antibodies in cell-based imaging assays to monitor transporter trafficking in response to drug candidates.

• Mechanism of action studies:

  • Investigate how drug candidates affect SLC6A16 protein levels, post-translational modifications, or subcellular localization.

  • Combine with functional transport assays to correlate protein changes with functional outcomes.

• Drug-target interaction analysis:

  • Use conformation-specific antibodies to detect drug-induced conformational changes in SLC6A16.

  • Apply antibody-based approaches like cellular thermal shift assays (CETSA) to confirm direct binding of compounds to SLC6A16.

• Biomarker development:

  • Develop quantitative assays to monitor SLC6A16 expression as a potential biomarker for disease progression or treatment response.

  • The SLC6 family's association with various neurological and psychiatric disorders makes SLC6A16 a potential biomarker candidate.

• Therapeutic antibody development:

  • Evaluate potential for developing therapeutic antibodies targeting accessible extracellular domains of SLC6A16.

  • Screen for antibodies that can modulate transporter function for therapeutic benefit.

• Safety assessment:

  • Monitor off-target effects of therapeutics on SLC6A16 expression or function.

  • Investigate potential compensatory changes in related transporters in response to SLC6A16-targeted therapies.

The SLC6 family's involvement in numerous human diseases and disorders, including ADHD, X-linked mental retardation, addiction, Tourette syndrome, schizophrenia, Parkinson's disease, and autism , makes SLC6A16 an important research target for therapeutic development.

What methods can be used to study SLC6A16 oligomerization and protein-protein interactions?

Several antibody-based methods can be employed to investigate SLC6A16 oligomerization and protein-protein interactions:

• Co-immunoprecipitation (Co-IP):

  • Use SLC6A16 antibodies to pull down the protein complex and identify interacting partners by Western blotting or mass spectrometry.

  • Reciprocal Co-IP with antibodies against suspected interacting proteins can confirm interactions.

• Proximity Ligation Assay (PLA):

  • Detect protein-protein interactions within 40 nm using pairs of primary antibodies and specialized secondary antibodies.

  • Particularly useful for detecting SLC6A16 interactions in situ within cells or tissues.

• Förster Resonance Energy Transfer (FRET):

  • Combine SLC6A16 antibodies labeled with donor and acceptor fluorophores to detect protein proximity.

  • Can be applied in fixed cells or in solution with purified proteins.

• Bimolecular Fluorescence Complementation (BiFC):

  • When studying tagged versions of SLC6A16, antibodies can be used to verify expression and localization of fusion proteins.

• Chemical crosslinking followed by immunoprecipitation:

  • Stabilize transient interactions with crosslinkers before immunoprecipitation with SLC6A16 antibodies.

  • Analyze crosslinked complexes by Western blotting or mass spectrometry.

• Blue Native PAGE:

  • Use native conditions to preserve protein complexes, followed by Western blotting with SLC6A16 antibodies to detect oligomeric states.

• Size Exclusion Chromatography combined with Western blotting:

  • Separate protein complexes by size, then use SLC6A16 antibodies to detect the protein in different fractions.

• Single-molecule imaging techniques:

  • Apply fluorescently labeled antibody fragments in super-resolution microscopy to visualize SLC6A16 clustering and organization.

These approaches are particularly relevant given evidence that oligomerization can impact proper trafficking of SLC6 transporters to the plasma membrane and may modulate function, regulation, and response to drugs .

How do epigenetic and post-translational modifications affect SLC6A16, and how can antibodies help investigate these mechanisms?

Investigating epigenetic and post-translational modifications of SLC6A16 requires specialized antibody-based approaches:

• Post-translational modifications (PTMs):

  • Glycosylation: Use glycosylation-specific antibodies or enzymatic deglycosylation followed by Western blotting to detect shifts in molecular weight. SLC6 transporters are known to undergo glycosylation, which may affect their function and trafficking .

  • Phosphorylation: Apply phospho-specific antibodies targeting predicted phosphorylation sites in SLC6A16, particularly in the intracellular domains. SLC6 transporters contain consensus intracellular phosphorylation sites that may regulate function .

  • Palmitoylation: Detect palmitoylation through biotin-switch assays followed by Western blotting with SLC6A16 antibodies. Palmitoylation is a known modification in SLC6 transporters that may affect membrane association .

  • Ubiquitination: Use ubiquitin-specific antibodies in co-immunoprecipitation experiments with SLC6A16 antibodies to detect this modification, which may regulate protein degradation.

• Epigenetic regulation:

  • Chromatin immunoprecipitation (ChIP): Use antibodies against histone modifications or transcription factors, followed by PCR for SLC6A16 promoter regions to investigate epigenetic regulation.

  • DNA methylation analysis: Combine bisulfite sequencing of the SLC6A16 promoter with protein expression analysis using SLC6A16 antibodies to correlate methylation status with expression levels.

  • miRNA regulation: Correlate miRNA expression with SLC6A16 protein levels detected by Western blotting to identify potential post-transcriptional regulation.

• Transgenerational effects:

  • Use SLC6A16 antibodies to assess protein expression in different generations of animal models exposed to environmental factors to investigate potential transgenerational epigenetic effects.

• Methodological approaches:

  • Mass spectrometry following immunoprecipitation: Use SLC6A16 antibodies to enrich the protein, followed by mass spectrometry to comprehensively identify PTMs.

  • 2D gel electrophoresis: Separate proteins by charge and size to detect different PTM-modified forms, followed by Western blotting with SLC6A16 antibodies.

  • Pulse-chase experiments: Combine with immunoprecipitation using SLC6A16 antibodies to study protein turnover and stability as affected by PTMs.

These approaches align with the emerging understanding of epigenetic and transgenerational mechanisms in regulating SLC6 transporters, which have been highlighted as important areas of research .